Section of Epidemiology and Population Science, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149 Trieste, Italy.
Int J Mol Sci. 2020 Mar 16;21(6):2011. doi: 10.3390/ijms21062011.
Breast cancer (BC) is the most frequent form of malignancy and second only to lung cancer as cause of deaths in women. Notwithstanding many progresses made in the field, metastatic BC has a very poor prognosis. As therapies are becoming more personalized to meet the needs of patients, a better knowledge of the molecular biology leading to the disease unfolds the possibility to project more precise compounds or antibodies targeting definite alteration at the molecular level and functioning on such cancer-causing molecules expressed in cancer cells of patients, or present as antigens on the surface of cancer cell membranes. Fibroblast growth factor receptor (FGFR) is one of such druggable targets, activated by its own ligands -namely the Fibroblast Growth Factors (FGFs). This pathway provides a vast range of interesting molecular targets pursued at different levels of clinical investigation. Herein we provide an update on the knowledge of genetic alterations of the receptors in breast cancer, their role in tumorigenesis and the most recent drugs against this particular receptor for the treatment of the disease.
乳腺癌（BC）是最常见的恶性肿瘤形式，仅次于肺癌，是女性死亡的第二大原因。尽管在该领域取得了许多进展，但转移性 BC 的预后仍然非常差。随着治疗方法越来越个性化以满足患者的需求，对导致疾病的分子生物学的更好了解为针对特定分子水平上的明确改变的更精确化合物或抗体提供了可能性，并针对在患者癌细胞中表达的或作为癌细胞表面上的抗原存在的致癌分子起作用。成纤维细胞生长因子受体（FGFR）就是这样一个可用药的靶点之一，它被自身配体——即成纤维细胞生长因子（FGFs）激活。该途径提供了广泛的有趣的分子靶点，在不同的临床研究水平上进行研究。本文综述了乳腺癌中受体的遗传改变、它们在肿瘤发生中的作用以及针对该特定受体的最新药物，以治疗该疾病。
